Invited to Present Updated Endometrial Cancer Data During Special Session “ASCO Plenary Series: Rapid Abstract Updates”
NEWTON, Mass., April 24, 2024 /PRNewswire/ — Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that several abstracts detailing new selinexor data have been selected for presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO Annual Meeting) being held May 31 – June 4 in Chicago, IL. The Company is pleased to have received an invitation to present updated Endometrial Cancer data during a special session called “ASCO Plenary Series: Rapid Abstract Updates.”
A highlight at the 2024 ASCO Annual Meeting includes a rapid oral abstract update of long-term follow-up of selinexor maintenance in patients with TP53wt advanced or recurrent endometrial cancer – a pre-specified subgroup analysis from the Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study.
“As we follow the endometrial cancer patients whose tumors are TP53wt and evaluate the long-term benefit, our confidence for selinexor to provide meaningful benefit for patients continues to grow,” said Reshma Rangwala, MD, PhD, Chief Medical Officer of Karyopharm. “We are excited about the advancement of our three, phase three programs in areas of high unmet need in endometrial cancer, myelofibrosis, and multiple myeloma.”
Details for the 2024 ASCO Annual Meeting abstracts are as follows:
| Abstract Title | Presentation Type | Abstract # | Session Date/Time |
| Endometrial Cancer | |||
| Updates on Abstract 427956: Long-Term
Follow up of Selinexor Maintenance in Patients with TP53wt Advanced or Recurrent Endometrial Cancer—A Pre- Specified Subgroup Analysis from the Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study (Rapid abstract update presentation following July 25, 2023 Plenary Series) |
Rapid Oral | 427956 |
June 1, 2024
12:30pm-1:30pm CDT |
| Phase 3 Dose Selection for Selinexor in
TP53wt Endometrial Cancer Based on Exposure-Response Analysis |
Poster | 5594 |
June 3, 2024
9:00am – 12:00pm CDT |
| Myelofibrosis | |||
| Phase 3 Trial Design: Randomized
Double-Blind Study Evaluating Selinexor, an XPO1 inhibitor, Plus Ruxolitinib in Jaki- Naïve Myelofibrosis |
Poster | TPS6594 |
June 3, 2024
9:00am – 12:00pm CDT |
| Phase 2 Study Trial Design: Evaluating
Selinexor Monotherapy in Patients with Jaki-Naïve Myelofibrosis and Moderate Thrombocytopenia |
Poster | TPS6593 |
June 3, 2024
9:00am – 12:00pm CDT |
About XPOVIO® (selinexor)
XPOVIO is a first-in-class, oral exportin 1 (XPO1) inhibitor and the first of Karyopharm’s Selective Inhibitor of Nuclear Export (SINE) compounds to be approved for the treatment of cancer. XPOVIO functions by selectively binding to and inhibiting the nuclear export protein XPO1. XPOVIO is approved in the U.S. and marketed by Karyopharm in multiple oncology indications, including: (i) in combination with Velcade® (bortezomib) and dexamethasone (XVd) in patients with multiple myeloma after at least one prior therapy; (ii) in combination with dexamethasone in patients with heavily pre-treated multiple myeloma; and (iii) in patients with diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy. XPOVIO (also known as NEXPOVIO® in certain countries) has received regulatory approvals in a growing number of ex-U.S. territories and countries, including Europe, the United Kingdom, South Korea, Israel, Singapore, Hong Kong, Mainland China, Australia, Canada, Taiwan and Macau and is marketed in those areas by Karyopharm’s global partners. Selinexor is also being investigated in several other mid- and late-stage clinical trials across multiple high unmet need cancer indications, including in endometrial cancer and myelofibrosis.
